Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein

Biological and Pharmaceutical Bulletin

Volumn 31, Issue 2, 2008, Pages 231-234

  Wang, Jun Sheng ^a,c   Zhu, Hao Jie ^b   Gibson, Bryan Bradford ^a   Markowitz, John Seth ^b   Donovan, Jennifer Lyn ^a   DeVane, Carl Lindsay ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Antidepressant; Blood brain barrier; Bupropion; Desmethylsertraline; P glycoprotein; Sertraline

Indexed keywords

ADENOSINE TRIPHOSPHATASE; AMFEBUTAMONE; DRUG METABOLITE; ERYTHROAMINO ALCOHOL; GLYCOPROTEIN P; HYDROXY METABOLITE; NORSERTRALINE; SERTRALINE; THREO AMINO ALCOHOL; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; CONCENTRATION RESPONSE; DRUG BINDING; DRUG INHIBITION; ENZYME ASSAY; MICHAELIS MENTEN KINETICS; PROTEIN EXPRESSION;

ADENOSINE TRIPHOSPHATASES; ALGORITHMS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BLOOD-BRAIN BARRIER; BUPROPION; DATA INTERPRETATION, STATISTICAL; HUMANS; P-GLYCOPROTEIN; PROTEIN BINDING; SERTRALINE;

EID: 38849168733     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.31.231     Document Type: Article

References (29)

1. Cordon-Cardo C., O'Brien J. P., Casals D., Rittman-Grauer L., Biedler J. L., Melamed M. R., Bertino J. R., Proc. Natl. Acad. Sci. U.S.A., 86, 695-698 (1989).
2. Silverman J. A., "Metabolic Drug Interactions," ed. by Levy R., Lippincott-Raven Press, Philadelphia, 2000.
3. Sun H., Dai H., Shaik N., Elmquist W. F., Adv. Drug Deliv. Rev., 55, 83-105 (2003).
4. Kunta J. R., Sinko P. J., Curr. Drug Metab., 5, 109-124 (2004).
5. Schinkel A. H., Smit J. J., van Tellingen O., Beijnen J. H., Wagenaar E., van Deemter L., Mol C. A., van der Valk M. A., Robanus-Maandag E. C., te Riele H. P. J., Berns A. J. M., Borst P., Cell, 77, 491-502 (1994).
6. Schinkel A. H., Wagenaar E., Mol C. A., van Deemter L., J. Clin. Invest., 97, 2517-2524 (1996).
7. Schinkel A. H., Mayer U., Wagenaar E., Mol C. A., van Deemter L., Smit J. J., van der Valk M. A., Voordouw A. C., Spits H., van Tellingen O., Zijlmans J. M., Fibbe W. E., Borst P., Proc. Natl. Acad. Sci. U.S.A., 94, 4028-4033 (1997).
8. Kim R. B., Fromm M. F., Wandel C., Leake B., Wood A. J., Roden D. M., Wilkinson G. R., J. Clin. Invest., 101, 289-294 (1998).
9. Uhr M., Steckler T., Yassouridis A., Holsboer F., Neuropsychopharmacology, 22, 380-387 (2000).
10. Uhr M., Grauer M. T., J. Psychiatr. Res., 37, 179-185 (2003).
11. Uhr M., Grauer M. T., Holsboer F., Biol. Psychiatry, 54, 840-846 (2003).
12. Wang J. S., Run Y., Taylor R., Donovan L. J., Markowitz S. J., DeVane C. L., Psychopharmacology, 173, 132-138 (2004).
13. Wang J. S., Taylor R., Run Y., Donovan L. J., Markowitz S. J., DeVane C. L., Neuropsychopharmacology, 29, 551-557 (2004).
14. Mayer U., Wagenaar E., Dorobek B., Beijnen J. H., Borst P., Schinkel A. H., J. Clin. Invest., 100, 2430-2436 (1997).
15. Polli J. W., Jarrett J. L., Studenberg S. D., Humphreys J. E., Dennis S. W., Brouwer K. R., Woolley J. L., Pharm. Res., 16, 1206-1212 (1999).
16. Choo E. F., Leake B., Wandel C., Imamura H., Wood A. J., Wilkinson G. R., Kim R. B., Drug Metab. Dispos., 28, 655-660 (2000).
17. Feighner J. P., J. Clin. Psychiatry, 60 (Suppl. 4), 4-11 (1999).
18. Stormer E., von Moltke L. L., Perloff M. D., Greenblatt D. J., J. Clin. Pharmacol., 41, 708-714 (2001).
19. Boulton D. W., DeVane C. L., Liston H. L., Markowitz J. S., Life Sci., 71, 163-169 (2002).
20. Ambudkar S. V., Dey S., Hrycyna C. A., Ramachandra M., Pastan I., Gottesman M. M., Annu. Rev. Pharmacol. Toxicol., 39, 361-398 (1999).
21. Wang J. S., Zhu H. J., Markowitz J. S., Donovan J. L., DeVane C. L., Psychopharmacology, 187, 415-423 (2006).
22. Wang J. S., DeVane C. L., Bryan G. B., Donovan J. L., Markowitz J. S., Psychopharmacology, 183, 400-409 (2006).
23. Wang J. S., Ruan Y., Taylor R. M., Donovan J. L., Markowitz J. S., DeVane C. L., Int. J. Neuropsychopharmacol., 7, 415-419 (2004).
24. Weiss J., Dormann S. M., Martin-Facklam M., Kerpen C. J., Ketabi-Kiyanvash N., Haefeli W. E., J. Pharmacol. Exp. Ther., 305, 197-204 (2003).
25. Hendrick V., Stowe Z. N., Altshuler L. L., Hwang S., Lee E., Haynes D., Am. J. Psychiatry, 160, 993-996 (2003).
26. Zhu H. J., Wang J. S., Markowitz J. S., Donovan J. L., Gibson B. B., DeVane C. L., Neuropsychopharmacology, 32, 757-764 (2007).
27. Hogeland G. W., Swindells S., McNabb J. C., Kashuba A. D., Yee G. C., Lindley C. M., Clin. Pharmacol. Ther., 81, 69-75 (2007).
28. Uhr M., Grauer M. T., J. Psychiatr. Res., 37, 179-185 (2003).
29. Juurlink D. N., Mamdani M. M., Kopp A., Herrmann N., Laupacis A., Br. J. Clin. Pharmacol., 59, 102-107 (2005).